drugset / Trial / NCT01430572
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Phase 1
Completed
62 enrolled
M.D. Anderson Cancer Center
GlaxoSmithKline · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of Votrient (pazopanib) and Afinitor (everolimus) that can be given to patients with advanced cancer. The safety of these drugs will also be studied. Pazopanib is designed to block different receptors in the cancer cells that ultimately are responsible for the growth of the tumor and its blood vessels. Everolimus is designed to block a protein called mTOR inside the cancer cells, which is also involved in cancer growth.
Timeline
- Start
- 2011-10-07
- Primary completion
- 2020-05-12
- Completion
- 2020-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Pazopanib | Small molecule | 200 mg | Oral |